Novel compositions for the treatment of IRDS and ARDS are indicated which contain N-(3,5-dichloro-pyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide and/or its pharmacologically tolerable salts and lung surfactant.
1. A method for preparation of a medicament composition in powder form for treatment of IRDS (Infant Respiratory Distress Syndrome) or ARDS (Adult Respiratory Distress Syndrome), the composition comprising at least one phospholipid-comprising lung surfactant and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide or a pharmaceutically tolerable salt thereof, wherein the method comprises either:
i) a) lyophilizing an admixture of a liquid phospholipid-comprising lung surfactant preparation with an aqueous suspension of N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide or a pharmaceutically tolerable salt thereof, to obtain a lyophilized product, and
b) micronizing the lyophilized product to obtain the composition in powder form; or
ii) a) lyophilizing a solution in a suitable solvent of the phospholipid-comprising lung surfactant and of the N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide or the pharmaceutically tolerable salt thereof, to obtain a lyophilized product, and
b) micronizing the lyophilized product to obtain the composition in powder form; or
iii) spray-drying an admixture of an aqueous suspension of the phospholipid-comprising lung surfactant and an aqueous suspension of the N-(3,5-dichloropyrid-4-yl)-3- cyclopropyl-methoxy-4-difluoromethoxybenzamide to obtain the composition in powder form; or
iv) spray-drying a solution of the phospholipid-comprising lung surfactant and the N-(3,5-dichloropyrid-4-yl) -3-cyclopropylmethoxy-4-difluoromethoxybenzamide in a suitable solvent, wherein the N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxy-benzamide is optionally in the form of a pharmaceutically tolerable salt thereof, to obtain the composition in powder form.
2. The method as claimed in claim 1 , wherein the phospholipid-comprising lung surfactant comprises a lung surfactant protein C.
3. The method as claimed in claim 1 , wherein the phospholipid-comprising lung surfactant comprises a recombinant lung surfactant protein C (r-SP-C).
4. The method as claimed in claim 1 , wherein the phospholipid-comprising lung surfactant comprises recombinant lung surfactant protein C mutant r-SP-C (FF/I).
5. In a method for treating a subject afflicted with IRDS (Infant Respiratory Distress Syndrome) or ARDS (Adult Respiratory Distress Syndrome) comprising administering to the subject an effective amount of a pharmaceutical composition comprising N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide or a pharmaceutically tolerable salt thereof, the improvement wherein the composition further comprises at least one phospholipid-comprising lung surfactant.
6. The method of claim 5 , wherein the composition is in powder form.
7. The method of claim 5 , wherein administration is by inhalation.